Nektar Therapeutics logo

Nektar Therapeutics

NASDAQ:NKTR

Overview | Financials
Company Name Nektar Therapeutics
Symbol NKTR
Currency USD
Price 1.38
Market Cap 253,947,600
Dividend Yield 0%
52-week-range 0.41 - 1.93
Industry Biotechnology
Sector Healthcare
CEO Mr. Howard W. Robin
Website https://www.nektar.com

An error occurred while fetching data.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder

Related Stocks

Codexis, Inc. logo

Codexis, Inc.

CDXS

3.7 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

12.31 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

25.33 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.526 USD

Merus N.V. logo

Merus N.V.

MRUS

54.19 USD

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

7.4 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

10.52 USD

Financials

Numbers are in millions USD

Numbers are in millions USD